Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I6UU
|
|||
| Former ID |
DIB003540
|
|||
| Drug Name |
UK-74505
|
|||
| Synonyms |
rac-Modipafant; UK-74505; Modipafant racemate; 122956-68-7; UK 74505; 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-((2-pyridinylamino)carbonyl)-, ethyl ester; UK 80067; Modipafant (racemate); AC1L2W8B; C34H29ClN6O3; SCHEMBL6995473; AN-3660; LS-172547; KB-276046; FT-0672447; ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(2-pyridylcarbamoyl)-1,4-dihydropyridine-3-carboxylate; ethyl 4-(2-chlorophenyl)-6-methyl-2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sepsis [ICD-11: 1G40-1G41; ICD-10: R57.2; ICD-9: 785.52] | Discontinued in Phase 2 | [1] | |
| Company |
Pfizer Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H29ClN6O3
|
|||
| Canonical SMILES |
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)NC3=CC=CC=N3)C)C4=CC=C(C=C4)N5C(=NC6=C5C=CN=C6)C
|
|||
| InChI |
1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)
|
|||
| InChIKey |
ODRYSCQFUGFOSU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 122956-68-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Platelet-activating factor receptor (PTAFR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Staphylococcus aureus infection | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (q) signalling events | ||||
| Interferon gamma signaling | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Interferon gamma signaling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001719) | |||
| REF 2 | Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin. Br J Pharmacol. 1994 Oct;113(2):513-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.